Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine 2001 June;45(2) > The Quarterly Journal of Nuclear Medicine 2001 June;45(2):139-52

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints

 

  RADIOPHARMACOLOGY 

The Quarterly Journal of Nuclear Medicine 2001 June;45(2):139-52

Copyright © 2009 EDIZIONI MINERVA MEDICA

language: English

Brain radioligands - State of the art and new trends

Halldin C., Gulyás B., Langer O., Farde L.

From the Karolinska Institutet, Department of Clinical Neuroscience, Psychiatry Section, Karolinska Hospital, Stockholm, Sweden


PDF


Non-inva­sive radio­ligand ­imaging ­methods for ­brain ­receptor ­studies use ­either ­short-­lived posi­tron-emit­ting radio­nu­clides ­such as 11C and 18F for posi­tron emis­sion tomog­raphy (PET) or ­single ­photon-emit­ting radio­nu­clides ­such as 123I for ­single ­photon emis­sion com­puted tomog­raphy (­SPECT). PET and ­SPECT use radio­lig­ands ­which are ­injected intra­ve­nously ­into experi­mental ani­mals, ­human vol­un­teers or ­patients. The ­main appli­ca­tions of radio­lig­ands in ­brain ­research con­cern ­human neu­ro­psy­cho­phar­ma­cology and the dis­covery and devel­op­ment of ­novel ­drugs to be ­used in the ­therapy of neu­ro­log­ical and psy­chi­atric dis­or­ders. A ­basic ­problem in PET and ­SPECT ­brain ­receptor ­studies is the ­lack of ­useful radio­lig­ands ­with appro­priate ­binding char­ac­ter­is­tics. Pre­req­ui­site cri­teria ­need to be sat­is­fied for a radio­ligand to ­reveal ­target ­binding ­sites in ­vivo. ­This sec­tion ­will dis­cuss ­these impor­tant cri­teria and ­also ­review ­recent exam­ples in neu­ro­re­ceptor radio­ligand devel­op­ment ­such as selec­tive radio­lig­ands for ­brain mono­amine trans­porters.

top of page